 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
3795 News |  |
| «12...89101112131415161718...4546» |
- || dimethyl fumarate / Generic mfg.
Preclinical, Review, Journal: Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases. (Pubmed Central) - Jun 9, 2022
Most of the studies are concerned with cellular or animal models of Alzheimer's disease (AD) and Parkinson's disease (PD), one utilized a mouse model of Huntington's disease (HD) and one clinical trial was carried out with amyotrophic lateral sclerosis (ALS) patients. The discrepancies in the results of the various studies are discussed, and issues requiring further research have been identified.
- | Niagen (nicotinamide riboside) / ChromaDex
Journal: A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models. (Pubmed Central) - Jun 8, 2022
Eight single drug molecules were administered to FA fibroblast patient cells: nicotinamide riboside, hemin, betamethasone, resveratrol, epicatechin, histone deacetylase inhibitor 109, methylene blue, and dimethyl fumarate...Therefore, they could be a valuable combination to counteract FA pathophysiology. Further studies will help fully understand the potential of a combined therapeutic strategy in FA pathophysiology.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Phase classification, Trial completion date, Trial primary completion date: haojunwei3: Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke (clinicaltrials.gov) - Jun 6, 2022
P1/2, N=50, Recruiting, Sponsor: Xuanwu Hospital, Beijing
Further studies will help fully understand the potential of a combined therapeutic strategy in FA pathophysiology. Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || dimethyl fumarate / Generic mfg.
Review, Journal: Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. (Pubmed Central) - Jun 4, 2022
The effects of inflammation and oxidative stress are detailed in respect of AEA and 2-AG levels, via effects on calcium homeostasis and phospholipase A activity; on FAAH activity, via nitrosylation/nitration of functional cysteine and/or tyrosine residues; and on 2-AG activity via effects on MGLL expression and MAGL. Finally, based on these detailed molecular neurobiological mechanisms, it is suggested that cannabidiol and dimethyl fumarate may have therapeutic potential for major depressive disorder, bipolar disorder and schizophrenia.
- || dimethyl fumarate / Generic mfg.
@biogen pq avoir encore agrandit les boîtes de tecfidera ? 0 écologie... (Twitter) - Jun 1, 2022
- morphine sulphate / Generic mfg., dimethyl fumarate / Generic mfg.
Effects of Dimethylfumarate on Morphine Withdrawal Symptoms and In Vivo Neurochemistry in Morphine-Dependent Mice: A Behavioral and Proton Magnetic Resonance Spectroscopy Study (Marquette Ballroom) - Jun 1, 2022 - Abstract #CPDD2022CPDD_494;
Since taurine inhibits glutamate neurotransmission and attenuates sympathetic nervous system activity and gut leakiness, drivers of opioid withdrawal symptom severity, DMF's beneficial effects in males could result from its enhancement of taurine levels. Like DMF, taurine has anti-inflammatory effects that also could reduce morphine withdrawal symptoms.
- | Mayzent (siponimod) / Novartis
Journal, HEOR: Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. (Pubmed Central) - May 31, 2022
Incremental cost-effectiveness ratios (ICERs), calculated as cost per QALY, for siponimod versus natalizumab (dominant), ocrelizumab (£4,760), fingolimod (£10,033) and dimethyl fumarate (£15,837) indicated that siponimod was cost-effective at the commonly accepted willingness-to-pay threshold of £30,000/QALY. Recognition of active SPMS, and treatment of this phenotype with siponimod offers a cost-effective and clinically beneficial treatment approach compared with continuation of oral or infused RRMS DMTs.
- | dimethyl fumarate / Generic mfg.
Observational data, Retrospective data, Journal: Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study. (Pubmed Central) - May 30, 2022
Recognition of active SPMS, and treatment of this phenotype with siponimod offers a cost-effective and clinically beneficial treatment approach compared with continuation of oral or infused RRMS DMTs. The very low incidence of functional TD indicates an overall very good thyroid tolerance of DMF, arguing against screening for TD in MS patients considered for or treated with DMF, and supporting the further study of Nrf2 activators for the prevention and treatment of TD.
- || dimethyl fumarate / Generic mfg.
Review, Journal: Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise. (Pubmed Central) - May 30, 2022
The findings of these studies need to be assessed in larger prospective clinical trials, ideally with a double-blind randomized study design, investigating the effects on cardiovascular endpoints as well as morbidity and mortality. The long-term impact of DMF therapy on cardiovascular diseases also needs to be confirmed.
- | bardoxolone methyl (RTA 402) / Kyowa Kirin, Reata
Preclinical, Journal: Nrf2 Activation With CDDO-Methyl Promotes Beneficial and Deleterious Clinical Effects in Transgenic Mice With Sickle Cell Anemia. (Pubmed Central) - May 29, 2022
Pulmonary vessels isolated from SS mice treated for 4 months with CDDO-Me displayed a diminished response to nitric oxide (NO)-induced vasodilation compared to littermates given vehicle...Endothelin signaling is associated with increased vascular tone and vasoconstriction. This study underscores the importance of pre-clinical benefit-risk investigations of Nrf2 activating compounds which may be used to treat patients with SCD.
- ||||| dimethyl fumarate / Generic mfg.
Biomarker: Really cool. Nasal (but not oral) dimethyl fumarate (DMF) rescues lung Nrf2 expression levels, ⬇️ lung oxidative stress, and ⬆️ the resolution of age-dependent established fibrosis. Kudos Drs Kato, Hecker & team #DrugRepurposing4PF #CureIPF https://t.co/iCe2krzqlw (Twitter) - May 26, 2022
- | dimethyl fumarate / Generic mfg.
Preclinical, Journal: Dimethyl fumarate ameliorates stress urinary incontinence by reversing ECM remodeling via the Nrf2-TGF-β1/Smad3 pathway in mice. (Pubmed Central) - May 25, 2022
This study underscores the importance of pre-clinical benefit-risk investigations of Nrf2 activating compounds which may be used to treat patients with SCD. Dimethyl fumarate can ameliorate urethra closure dysfunction in the VD-induced SUI mice model, and the therapeutic effect of DMF is mediated by the Nrf2-dominated antioxidant system and its downstream TGF-β1/Smad3 signaling pathway.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina. (Pubmed Central) - May 25, 2022
Our study shows that EHE therapies prevent disease progression, relapses, and new MRI lesions and demonstrated no increased risk of specific adverse events when compared with ES therapy. These data should be considered when selecting a specific treatment for MS patients.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019. (Pubmed Central) - May 25, 2022
DMT cost is a key driver of the overall healthcare expenditure in MS. Future comparative and cost-effectiveness studies integrating claims and electronic health records data with better balancing of patient characteristics are warranted.
- | dimethyl fumarate / Generic mfg.
Preclinical, Journal: A comparison study between dimethyl itaconate and dimethyl fumarate in electrophilicity, Nrf2 activation, and anti-inflammation in vitro. (Pubmed Central) - May 19, 2022
However, DMI demonstrated poor anti-inflammatory effects in Jurkat cells, bone marrow-derived dendritic cells, and RAW264.7 cells. Our study suggested that DMI was a potent electrophilic Nrf2 activator but was probably not a promising anti-inflammatory agent.
- | Tysabri (natalizumab) / Biogen, Ocrevus (ocrelizumab) / Roche, Biogen
Journal, Real-world evidence: Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry. (Pubmed Central) - May 18, 2022
It is conceivable that the number of self-reported symptoms indicates the need for more detailed clarification of the DMT characteristics and expectations of treatment outcomes. Injectable DMTs no longer play a major role in the treatment of RRMS in Switzerland and a trend toward an early use of potent drugs is emerging.
- | Observational data, Retrospective data, Journal: FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. (Pubmed Central) - May 18, 2022
Both demographic and clinical factors were associated with switching to oral DMAs. Further research is needed to evaluate the outcomes of switching to inform treatment decisions for MS management.
- | dimethyl fumarate / Generic mfg.
Biomarker, Journal: Immunological changes following electroconvulsive therapy in multiple sclerosis. (Pubmed Central) - May 18, 2022
In our patient with TRD and MS ECT was safe and feasible. We did not see any neurobiological signs of disease activation of MS or neurodegeneration during the course of ECT, which may even be beneficial as it led to increase in the neuroprotective CCL-2 pathway in the presented patient.
- | Journal: Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. (Pubmed Central) - May 18, 2022
Analysis of COVID-19 risk among all patients on the commonly used DMTs did not demonstrate increased risk of infection with any DMT. Rituximab was associated with increased risk for severe disease.
- | dimethyl fumarate / Generic mfg.
Journal: Impact of dimethylfumarate on sleep in multiple sclerosis patients: an actigraphic study. (Pubmed Central) - May 17, 2022
Actigraphy is a simple diagnostic tool, able to support an objective measure of sleep parameters. The simplicity of application may allow considering its use for a screening of sleep disorders in MS patients.
- | dimethyl fumarate / Generic mfg.
Journal: ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling. (Pubmed Central) - May 15, 2022
DTP@DMF NPs can reduce macrophage-mediated fibroblast-to-myofibroblast transition and extracellular matrix deposition to attenuate lung fibrosis by upregulating Nrf2 signaling. This ROS-responsive liposome is clinically promising as an ideal delivery system for inhaled drug delivery.
- | bardoxolone methyl (RTA 402) / Kyowa Kirin, Reata, Leukeran (chlorambucil) / GSK
Journal: To each their own: Disparate abilities of Nrf2 activators to protect against various electrophilic and oxidative insults. (Pubmed Central) - May 14, 2022
KI696 improved the cell's ability to survive chlorambucil. The ability of a given Nrf2 activator (or lack thereof) to protect against a given stressor points to a need to better understand the cytoprotective environment (specific enzymes upregulated, glutathione levels, etc.) that best protect against specific stressors.
- | dimethyl fumarate / Generic mfg.
Journal: Warburg Effect in Anopheles Mosquito Anti-Bacterial Immunity. (Pubmed Central) - May 14, 2022
By inhibiting the utilization of glycolysis and Warburg metabolism, decreased survival related to immune challenge is observed, showing Warburg metabolism is crucial for mosquito immunity. We believe current cancer therapeutics targeting Warburg metabolism can be an effective vector control strategy to prevent mosquito-borne diseases.
- | dimethyl fumarate / Generic mfg.
Journal: Ethanol Inhibits the Metabolism of the Multiple Sclerosis Drug Dimethyl Fumarate to its Active Metabolite and Decreases Brain Exposure. (Pubmed Central) - May 14, 2022
Ethanol inhibits the hydrolysis of dimethyl fumarate to active monomethyl fumarate by carboxylesterase 1 and has a drastic effect on the disposition of dimethyl fumarate and monomethyl fumarate. The therapeutic effect of dimethyl fumarate is likely to be significantly altered by the consumption of ethanol or other drug that inhibits carboxylesterase 1 potentially altering the beneficial effect of chronic dimethyl fumarate therapy on Relapsing-Remitting Multiple Sclerosis.
- | dimethyl fumarate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal, IO biomarker: Dimethyl Fumarate Ameliorates Doxorubicin-Induced Cardiotoxicity By Activating the Nrf2 Pathway. (Pubmed Central) - May 14, 2022
In conclusion, our data confirmed that DMF alleviated DOX-induced cardiotoxicity by regulating oxidative stress and apoptosis through the Nrf2 pathway. DMF may serve as a new candidate to alleviate DOX-related cardiotoxicity in the future.
- | bardoxolone methyl (RTA 402) / Kyowa Kirin, Reata
Journal, Combination therapy: Synergy of Nrf2-Activating Electrophiles in Combination with the Nrf2-Inhibitor KI696: A Model of Mechanistic Basis for Synergy. (Pubmed Central) - May 14, 2022
Through an ARE-reporter luminescence assay, we show that these three electrophiles each synergistically upregulate ARE-driven expression with KI696 in a statistically significant manner, based on our Dose Equivalence/Zero Interaction (DE/ZI) method (Repash et al., Frontiers in Pharmacology, 2021). The combination of these clinically-relevant electrophiles and KI696 are a model for mechanistic investigations of synergy and identification of targets other than Keap1 cysteines.
- | dimethyl fumarate / Generic mfg.
Journal: 7-deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signaling. (Pubmed Central) - May 12, 2022
All suggest that the potential of 7-d-GDN in suppression of inflammation, especially antagonizing RA severity. Our works support for drugs discovery in RA treatment.
- | dimethyl fumarate / Generic mfg.
Journal: Synthesis and cellular evaluation of click-chemistry probes to study the biological effects of alpha, beta-unsaturated carbonyls. (Pubmed Central) - May 12, 2022
It is shown using this approach that dimethylfumarate forms adducts with multiple intracellular targets including cytoskeletal, organelle and nuclear species, with these including the rate-limiting glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). This approach should be amenable to use with multiple α,β-unsaturated carbonyls and a wide variety of targets containing nucleophilic sites.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Timing Disease-Modifying Therapies with COVID-19 Vaccine in Multiple Sclerosis Patients: A Real-World Data (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_101;
The majority of patients had the correct timing with respect to getting DMTs and their vaccines. However, patients on "Induction DMTs" have postponed BD, probably due to time and method of getting DMTs.
- Mavenclad (cladribine) / EMD Serono
Progressive Multiple Sclerosis Treatment Patterns and Therapy Selection Considerations: Patient-Level Retrospective Chart Audit Data Comparison By Managing Physician Specialty (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_82;
Among specialists, a greater focus on reducing inflammatory disease activity drives less use of interferons, while tolerability and cost concerns maintain the reliance on GA agents. With no approved therapy for not active SPMS, specialists are especially likely to rely on high-efficacy oral DMTs approved for RMS.
- Vumerity (diroximel fumarate) / Biogen
Diroximel Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 Evolve-MS-1 Study (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_80;
P3
Clinical and radiological (Gd+ lesion counts) outcomes significantly improved, and no discontinuations due to GI AEs were seen. These data suggest that DRF is an effective treatment option for young adults with MS.
- Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche, Biogen
Impact of COVID-19 on Treatment Selection for Multiple Sclerosis (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_73;
Compared to pre-pandemic time period , no major change in prescribing habits was observed; 74% infusion therapy ( 47% Ocrevus , 21% Tysabri) and 26% self- administered therapies ( dimethyl fumarate 12.9 %, glatiramer acetate 7.3%)...Additionally, chart reviews are being conducted to assess prescribing changes due to COVID-19. Conclusions : The results of this study will be utilized to understand the prescribing practice changes due to COVID-19 and provide background for future outcomes-focused research studies for MS patients.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Real-World Utilization of Ofatumumab for Treatment of Multiple Sclerosis (MS): Trends Nine Months after FDA Approval (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_72;
Understanding the patient profile for those who initiated ofatumumab in real-world settings may help inform treatment decisions. Future studies on long-term effectiveness of OMB are needed.
- Fumaderm (dimethyl fumarate) / Biogen
Real-World Effectiveness and Safety after 5 Years of Dimethyl Fumarate Treatment in Black/African American and Hispanic/Latino American Patients with Multiple Sclerosis in Esteem (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_69;
Compared with the 12 months before DMF initiation, ARR was significantly lower up to 5 years after DMF initiation in Black/AA and H/L patients. DMF’s safety profile in these subgroups was consistent with the overall ESTEEM population, although lymphopenia was less pronounced in black/AA and H/L subgroups; these lymphocyte findings should be interpreted with caution as this study was not designed to compare lymphocyte changes between different patient subgroups.
- Vumerity (diroximel fumarate) / Biogen
Patient Experience on Diroximel Fumarate (DRF) from the Mymsteam Social Network: Considerations for Dmt Selection (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_67;
However, the decision to remain on a treatment is determined by efficacy and tolerability. Early real-world data suggest that DRF is well tolerated and the majority of DRF patients reported experiencing physical benefits.
- Immune Response to COVID-19 Vaccine in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_64;
The relative importance of both humoral and cell-mediated immunity to SARS-CoV-2 in the context of DMTs is crucial to understand, especially for PwMS who failed to seroconvert. Study Support: Biogen.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg., fingolimod / Generic mfg.
Profile of Patients with Multiple Sclerosis on Oral Disease-Modifying Therapies in North American Registry for Care and Research in Multiple Sclerosis (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_53;
Our results suggest that real-world patients taking oral DMTs are similar to patients with MS overall. As MS registries are growing and more treatment options become available, capturing high-quality, long-term data is increasingly important.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., fingolimod / Generic mfg.
Adherence to Dmts in Patients with Multiple Sclerosis across Health-System Specialty Pharmacies (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_50;
Patients who switched DMT during the study had lower adherence, indicating these patients may require close monitoring. Further research is needed to investigate the financial and clinical outcomes tied to adherence.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Treatment Patterns and Therapy Selection Drivers Comparison between Anti-CD20 Agents Among Multiple Sclerosis Patients Who Recently Switched Disease-Modifying Therapies (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_49;
OFA is more likely to be used later line compared to OCR and among patients where the once-monthly subcutaneous dosing profile was influential in the switch decision. RTX, used off label for the treatment of MS, was used in place of OCR when market access was a concern.
- evobrutinib (M2951) / EMD Serono
Evobrutinib Significantly Reduces Relapses and MRI Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_41;
P2
The data indicate that higher doses of evobrutinib reduce MRI activity, regardless of baseline NfL levels, and significantly reduce the proportion of patients with relapses versus placebo/low doses in the high blood NfL level group. These data also support the value of blood NfL levels as a prognostic marker of future disease activity.
- Mavenclad (cladribine) / EMD Serono
Patient Characteristics and Treatment Patterns Prior to Initiating Cladribine Tablets: A US Retrospective Commercial Claims Analysis (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_38;
Of those on DMTs in the 1-year pre-index period, patients switched from ocrelizumab (12.1%), fingolimod (10.3%), dimethyl fumarate (11.3%), natalizumab (9.2%), glatiramer acetate (7.4%), teriflunomide (7.6%), and subcutaneous interferon-beta 1a (5.0%). These results provide a better understanding of real-world patient characteristics and treatment patterns among US commercially insured patients receiving CladT.
- Vumerity (diroximel fumarate) / Biogen
Characterizing Early Real-World Experience of Narcoms Registry Participants Treated with Diroximel Fumarate (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_33;
No discontinuations due to GI side effects were observed. The effects of DRF on disability progression and patient-reported outcomes will be followed longitudinally.
- evobrutinib (M2951) / EMD Serono
Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a Phase II Trial (WOODROW WILSON D) - May 9, 2022 - Abstract #CMSC2022CMSC_2;
P2
Role of the Study Sponsor: This study was sponsored by EMD Serono Research and Development Institute, Inc. The study sponsor was involved in the study design, collection, analysis, and interpretation of data, and was involved in the decision to submit the abstract for publication.
- |||||| dimethyl fumarate / Generic mfg.
New trial: A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - May 9, 2022
P=N/A, N=172, Completed, Sponsor: Eisai Korea Inc.
- | dimethyl fumarate / Generic mfg.
Journal, PARP Biomarker: Dimethyl Fumarate Induces Apoptosis via Inhibiting NF-κB and STAT3 Signaling in Adult T-cell Leukemia/Lymphoma Cells. (Pubmed Central) - May 7, 2022
These results indicate that DMF inhibits proliferation and induces apoptosis in HTLV-1-infected and transformed T-cells by suppressing NF-κB and STAT3 signaling pathways. DMF should be investigated further as a novel agent for ATL.
- || glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
Clinical, Journal, Real-world evidence: Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. (Pubmed Central) - Apr 28, 2022
High adherence improved economic outcomes versus low adherence. Thus, investing in adherence improvement is beneficial to improve outcomes in relapsing multiple sclerosis.
- | dimethyl fumarate / Generic mfg.
Journal, HEOR: Comparative effectiveness of dimethyl fumarate in Multiple Sclerosis. (Pubmed Central) - Apr 27, 2022
Thus, investing in adherence improvement is beneficial to improve outcomes in relapsing multiple sclerosis. DMF is associated with lower risk of treated relapse for patients with RRMS than other first-line RRMS agents (TERI and IIM).
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Journal: Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages. (Pubmed Central) - Apr 26, 2022
DMI, 4OI, DMF and monomethyl fumarate (MMF), another fumarate derivative, also directly inhibited biochemical markers of NLRP3 activation in LPS-primed macrophages, mixed glia, OHSCs and human macrophages in response to nigericin and imiquimod, including ASC speck formation, caspase-1 activation, gasdermin D cleavage and IL-1β release...Together, these findings reveal the immunometabolic regulation of both the priming and activation steps of NLRP3 activation in macrophages. Furthermore, we highlight itaconate and fumarate derivatives as potential therapeutic options in NLRP3- and IL-1α-driven diseases, including in the brain.
- CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1706;
There were no differences in the utilization of IBD DMTs including mesalamine, azathioprine, anti-TNFs (infliximab, adalimumab, certolizumab pegol), and vedolizumab between the two groups.Three months after any IBD therapy initiation, UC patients with MS had higher all-cause mortality (OR: 1.87) and were more likely to need steroids (OR: 1.4) and plasma exchange...Natalizumab is indicated in both Crohn’s disease and MS and may also become an effective DMT for patients with both UC and MS. Future directions include stratifying disease outcomes based on different DMT utilization.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
CLINICAL CHARACTERISTICS, DISEASE-SPECIFIC OUTCOMES, AND MEDICATION UTILIZATION AMONG PATIENTS WITH CHRON’S DISEASE AND MULTIPLE SCLEROSIS IN THE USA: A MULTICENTER NETWORK STUDY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1705;
CD patients with MS were also more likely to use the following MS DMTs: natalizumab, glatiramer, interferon beta-1a and 1b, fingolimod, teriflunomide, dimethyl fumarate, ocrelizumab, and ofatumumab (Table 1).Three months after any IBD therapy initiation, CD patients with MS were more likely to need plasma exchange and undergo small intestine resections but were less likely to have fistulizing disease...Interestingly, they were also more likely to be prescribed TNF alpha-inhibitors. Future directions include stratifying the association with anti-TNFs from a temporal perspective and in terms of IBD and MS severity.